US 11,771,723 B2
Bifidobacterium longum NCIMB 41676
Eileen Frances Murphy, Cork (IE); Paul Enck, Berlin (DE); Christoph Braun, Tuebingen (DE); and Huiying Wang, Shanghai (CN)
Assigned to PrecisionBiotics Group Limited, Cork (IE)
Appl. No. 16/767,874
Filed by PrecisionBiotics Group Limited, Cork (IE)
PCT Filed Jan. 29, 2019, PCT No. PCT/EP2019/052138
§ 371(c)(1), (2) Date May 28, 2020,
PCT Pub. No. WO2019/145571, PCT Pub. Date Aug. 1, 2019.
Claims priority of application No. 18153993 (EP), filed on Jan. 29, 2018.
Prior Publication US 2020/0368296 A1, Nov. 26, 2020
Int. Cl. A61K 35/745 (2015.01); A23L 33/21 (2016.01); A23L 33/135 (2016.01); A61K 39/39 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)
CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A23L 33/21 (2016.08); A61K 39/39 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01)] 20 Claims
 
1. A method of treating a human subject, the method comprising administering to the subject an oral formulation comprising Bifidobacterium longum strain having the accession number NCIMB 41676 and an ingestible carrier, wherein the formulation improves or sustains vitality in the subject as measured by an increase in theta band resting state brain oscillations in the frontal and cingulate cortex and a decrease in beta-3 resting state brain oscillations in the hippocampus, fusiform, and temporal cortex.